Post-tuberculosis lung disease: Addressing the policy gap
Open Access
- 5 September 2024
- journal article
- essay
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 4 (9) , e0003560
Abstract
The burden of long-term functional impairment following curative treatment for tuberculosis (TB) constitutes a significant global health problem. By some estimates, chronic respiratory impairment, or post-tuberculosis lung disease (PTLD), is present in just over half of all patients who have completed TB therapy. Despite this high prevalence and substantial associated morbidity, discussion of PTLD is essentially absent from international and national TB policies and guidelines. Clear and ambitious clinical standards should be established for the diagnosis and management of PTLD, including the stipulation that all patients completing TB therapy should be screened for PTLD. Patients diagnosed with PTLD should receive linkage to chronic care, with access to inhalers and home oxygen, as indicated based on individual symptoms and pathophysiology. Leveraging their considerable influence, major funders, such as The Global Fund, could help close the gap in PTLD care by including PTLD in their strategic vision and funding streams. Immediate action is needed to address the substantial burden of disease associated with PTLD. This will require expanding the global approach to TB to include a commitment to diagnosing and treating long-term complications following initial curative therapy.Keywords
This publication has 25 references indexed in Scilit:
- A Global Tuberculosis Dictionary: unified terms and definitions for the field of tuberculosisThe Lancet Global Health, 2024
- Residual respiratory disability after successful treatment of pulmonary tuberculosis: a systematic review and meta-analysiseClinicalMedicine, 2023
- Post-tuberculosis pulmonary hypertension: a case of global disparity in health careThe Lancet Global Health, 2022
- Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelaeThe Lancet Global Health, 2021
- Pulmonary function in cured pulmonary tuberculosis casesIndian Journal of Tuberculosis, 2021
- Quantifying the global number of tuberculosis survivors: a modelling studyThe Lancet Infectious Diseases, 2021
- Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung DiseaseNew England Journal of Medicine, 2021
- Inhaled corticosteroids and the increased risk of pulmonary tuberculosis: a population-based case-control studyInternational Journal Of Clinical Practice, 2014
- The Health Systems Agenda: Prospects for the Diagonal Approach2014
- Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohortHeart, 2012